Baxter International Inc. (BAX)
Overview
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Explore More Data
Key Information
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Capital Structure (Updated: Nov 05 04:00 PM EST)
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date | 2025-10-30 |
| Earnings Call | 2025-10-30 |
| Avg EPS Estimate | 0.534 |
| Low EPS Estimate | 0.5176 |
| High EPS Estimate | 0.56 |
| Revenue | |
| Avg Revenue Forecast | 2,823,867,960 |
| Low Revenue Forecast | 2,798,190,000 |
| High Revenue Forecast | 2,879,540,000 |
BAX Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $1,686,000,000 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 0 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 0 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $9,724,999,680 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
BAX Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $2,228,000,000 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $0 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $0 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | 37.93% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | 9.73% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | -3.09% | Net profit margin, which reflects overall profitability. |
BAX Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 133.35% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $9,724,999,680 | Used together with cash and EBITDA to assess debt-paying ability. |
BAX Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | 5.00% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 0.00% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for BAX (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $17.95 | Latest stock trading price |
| Price Target (High) | $42 | Analyst highest expected price |
| Price Target (Low) | $19 | Analyst lowest expected price |
| Price Target (Average) | $24.07 | Average target price across analysts |
| Price Target (Median) | $22 | Median of target prices |
| Average Rating Score | 2.82 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | hold | Consensus rating |
| Analyst Coverage Count | 15 | Number of analysts providing estimates |
| Cash Holdings | $1,686,000,000 | Total cash held by the company |
| Cash per Share | $3.28 | Cash value per outstanding share |
| Total Debt | $9,724,999,680 | Company's total debt |
| Quick Ratio | 0 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 0 | Overall short-term liquidity |
| Debt/Equity Ratio | 133.35% | Leverage ratio: Debt / Equity |
| EBITDA | $2,228,000,000 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $11,022,999,552 | Total company revenue |
| Revenue per Share | $21.487 | Total revenue divided by shares outstanding |
| Gross Profit | 37.93% | Revenue minus cost of goods sold |
| Return on Assets | 0.00% | Net income / Total assets |
| Return on Equity | 0.00% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 0.00% | Year-over-year EPS growth |
| Revenue Growth (YoY) | 5.00% | Year-over-year revenue growth |
| Gross Margin | 37.93% | Gross profit / Total revenue |
| EBITDA Margin | 20.21% | EBITDA / Revenue |
| Operating Margin | 9.73% | Operating income / Revenue |
| Profit Margin | -3.09% | Net income / Revenue |
| Free Cash Flow | $0 | Cash left after capital expenditures |
| Operating Cash Flow | $0 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |